Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

US 12162861

Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use the

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12152038

Vasopressin receptor antagonists and products and methods related thereto

Neumora Therapeutics, Inc. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12134609

Quinoline cGAS antagonist compounds

The Board of Regents of the University of Texas System · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12115255

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12115166

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12115254

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12102640

Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal

United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12097196

Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12098144

Piperazine indazole glucocorticoid receptor antagonists

Corcept Therapeutics Incorporated · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12098141

Bicyclic indazole glucocorticoid receptor antagonists

Corcept Therapeutics Incorporated · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12091387

Quinoline cGAS antagonist compounds

The Board of Regents of the University of Texas System · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12090201

Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12071442

Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists

Nimbus Saturn, Inc. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12065416

cGAS antagonist compounds

The Board of Regents of the University of Texas System · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12064433

Pyridone A2R antagonists

Arcus Biosciences, Inc. · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12054487

Muscarinic acetylcholine M1 receptor antagonists

Contineum Therapeutics, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11986511

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11975045

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11944666

Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11926625

HPK1 antagonists and uses thereof

Nimbus Saturn, Inc. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11912786

Inhibitor of apoptosis protein (IAP) antagonists

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11897873

Kappa opioid receptor antagonists and products and methods related thereto

BLACKTHORN THERAPEUTICS, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11890289

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11878074

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)